![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 15, 11379-11382, April 14, 2000
From the Department of Clinical Laboratory Medicine, Faculty
of Medicine and the § Department of Pharmacognosy, Faculty
of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical
University, 2630 Sugitani, Toyama 930-0194, Japan
Heparin cofactor II (HCII) is a plasma serine
protease inhibitor whose ability to inhibit
Activation of Heparin Cofactor II by Calcium Spirulan*
,
-thrombin is accelerated
by a variety of sulfated polysaccharides in addition to heparin and
dermatan sulfate. Previous investigations have indicated that calcium
spirulan (Ca-SP), a novel sulfated polysaccharide, enhanced the rate of inhibition of
-thrombin by HCII. In this study, we investigated the
mechanism of the activation of HCII by Ca-SP. Interestingly, in the
presence of Ca-SP, an N-terminal deletion mutant of HCII (rHCII-
74)
inhibited
-thrombin, as native recombinant HCII (native rHCII) did.
The second-order rate constant for the inhibition of
-thrombin by
rHCII-
74 was 2.0 × 108
M
1 min
1 in the presence of 50 µg/ml Ca-SP and 10,000-fold higher than in the absence of Ca-SP. The
rates of native rHCII and rHCII-
74 for the inhibition of
-thrombin were increased only 80- and 120-fold, respectively. Our
results suggested that the anion-binding exosite I of
-thrombin was
essential for the rapid inhibition reaction by HCII in the presence of
Ca-SP and that the N-terminal acidic domain of HCII was not required.
Therefore, we proposed a mechanism by which HCII was activated
allosterically by Ca-SP and could interact with the anion-binding
exosite I of thrombin not through the N-terminal acidic domain of HCII.
The Arg103
Leu mutant bound to Ca-SP-Toyopearl with
normal affinity and inhibited
-thrombin in a manner similar to
native rHCII. These results indicate that Arg103 in HCII
molecule is not critical for the interaction with Ca-SP.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Clinical
Laboratory Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan. Tel.: 81-76-434-7387; Fax: 81-76-434-4501; E-mail: hayakawa@ms.toyama-mpu.ac.jp.
This article has been cited by other articles:
![]() |
F. Zhang, Y. Wu, Q. Ma, D. Hoppensteadt, J. Fareed, and R. J. Linhardt Studies on the Effect of Calcium in Interactions Between Heparin and Heparin Cofactor II Using Surface Plasmon Resonance Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 249 - 257. [Abstract] [PDF] |
||||
![]() |
I. M. Verhamme, P. E. Bock, and C. M. Jackson The Preferred Pathway of Glycosaminoglycan-accelerated Inactivation of Thrombin by Heparin Cofactor II J. Biol. Chem., March 12, 2004; 279(11): 9785 - 9795. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |